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Purpose: Biliary atresia (BA) is the most common indication of liver transplantation in   children. 
Pathogenesis of hepatic fibrosis, which is a prominent feature of BA, remains obscure. The 
purpose of this work was to determine the cellular sources of transforming growth factor beta-1 
(TGFβ1) and establish the relationship between TGFβ1-producing cells and extracellular matrix 
producing myofibroblasts (MFBs) in advanced BA.
Methods: Trichrome staining and immunohistochemistry were carried out to determine 
the expression pattern of collagen and TGFβ1 protein in explant liver specimens from 
patients with BA. The intensities of portal and lobular TGFβ1 expressions were compared. 
  Immunofluorescence technique was carried out to determine the relationship between α-smooth 
muscle actin (α-SMA)-positive-MFB and TGFβ1-positve cells.
Results: Lobular TGFβ1 protein expression was significantly higher than portal (89 ± 6 versus 
10 ± 1 arbitrary units, P # 0.05), whereas no difference was noted in livers used as control 
(10 ± 1.6 versus 19 ± 5 arbitrary units, P = 0.11). TGFβ1 expression was more in the center of 
nodules versus MFB in surrounding fibrous septa. Contrary to TGFβ1 expression, α1-SMA 
was mostly expressed in the portal structures and the adjacent fibrous septa enacting lobula-
tion of the parenchyma. The results obtained by coimmunofluorescence staining showed no 
colocalization of α-SMA and TGFβ1.
Conclusions: TGFβ1 protein expression is mostly localized to hepatocytes in advanced BA. These 
findings suggest a paracrine mechanisms of TGFβ1-driven fibrogenesis in advanced BA.
Keywords: biliary atresia, liver fibrosis, transforming growth factor β-1, liver transplantation
Introduction
Untreated biliary atresia (BA) is universally fatal, mandating timely diagnosis and 
expedited portoenterostomy operation. This procedure, despite its appeal at the time of 
initial diagnosis, permits long-term survival in only about 20% of the affected infants. 
Liver transplantation (LT) becomes necessary for the long-term survival of most of 
the affected children due to the complications of cirrhosis, such as portal hypertension 
and poor growth. Although the exact pathogenesis of BA remains elusive, it is gener-
ally agreed that BA phenotype can result from several distinct mechanisms of liver 
injury, provoking a stereotypic response comprising inflammation, bile duct prolifera-
tion, apoptosis, and fibrogenesis.1 In this context, it is not surprising that the extent 
of liver fibrosis is the most important predictor of the outcome of portoenterostomy 
procedure.2–4 However, despite its prime significance, the assessment and manage-
ment of liver fibrosis have not yet been incorporated in routine   postportoenterostomy Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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patient care, mostly due to poor understanding of the under-
lying mechanisms of progressive liver fibrosis. Conversely, 
significant progress has been made in understanding the 
pathogenesis of liver fibrosis due to diseases afflicting adult 
populations. As such, contrary to conventional dogma, liver 
fibrosis is now considered to be a reversible pathologic 
event, provided that underlying mechanisms are addressed 
in a timely manner.5–8 Similarly, a consensus has emerged 
for the pivotal role of hepatic stellate cells (HSCs) in liver 
fibrosis.9–12
Transforming growth factor β-1 (TGFβ1) is the master 
fibrogenic cytokine that is well known to be involved in 
liver fibrosis in a variety of liver diseases.13–15 Through its 
receptors on myofibroblasts (MFBs) and other cells, TGFβ1 
orchestrates key fibrogenic events, most notably expansion 
of the MFB pool, induction of extracellular matrix proteins, 
and inhibition of matrix metalloproteinases.16–20 However, 
disease-specific mechanisms driving TGFβ1 upregulation 
are not well understood. Given that downstream fibro-
genic actions of TGFβ1 are relatively well understood,10,21 
elucidation of its cellular sources is a critical initial step 
not only for understanding possible triggers but also to 
delineate the march of molecular events linking ongoing 
liver injury to fibrosis. For example, as with any other 
chronic liver disease, it is quite conceivable that the cel-
lular sources of TGFβ1 will vary according to the triggers 
determined by site, underlying mechanisms, and the extent 
of liver injury.
Reconstruction of the topology of events linking injury to 
repair (fibrosis) therefore requires successive examinations, 
which is an enterprise that is hampered by ethical restrictions 
on liver biopsies after portoenterostomy, thus limiting the 
scope of fibrosis assessment to explant specimens only. In 
this work, using explant specimens, we sought to determine 
whether TGFβ1 is predominantly produced in portal and 
periportal structures, which are the main sites of liver injury 
or hepatic lobular cells, situated distant from the site of injury, 
thereby indicating paracrine mechanisms of TGFβ1-driven 
fibrogenesis in advanced BA.
Materials and methods
To accomplish our goal, using explant specimens, we car-
ried out trichrome staining and immunohistochemistry to 
determine the hepatic expressions of collagen and TGFβ1 
proteins. To determine whether TGFβ1 is expressed by col-
lagen-producing MFB, immunofluorescence was performed 
to determine colocalization of TGFβ1 and α1 smooth muscle 
actin (α-SMA). α-SMA is commonly used as a marker of 
collagen-producing MFB, the main fibrogenic cell type with 
diverse origins, including HSCs.
Patient population  
and liver samples
After approval from the Institutional Review Board of the 
University of Florida (UF), FL, USA, patients with BA who 
required LT were identified from the UF liver transplant 
database. To determine the expression of markers of fibrosis 
in BA, liver sections were obtained from explant specimens 
archived from LT done between the years 2000 and 2008 
(N = 30; 16 males, 14 females). The mean age at the time 
of LT was 1.8 ± 0.369 years (range 2–17 years). Liver sec-
tions from archived sections of living related liver donors 
were used as controls. The alternative approach, using mar-
gins from hepatoblastoma resections as controls, was not 
pursued because our preliminary work indicated extensive 
and inconsistent expression of fibrogenic cytokines in these 
‘healthy margins’. Therefore, albeit age-related limitations, 
healthy human liver sections were used as controls in this 
study. All biopsied specimens were 4 µm thick, fixed in 
phosphate-buffered formalin, and embedded in paraffin. 
Serial adjacent sections were used for hematoxylin and eosin 
staining, trichrome staining, immunohistochemistry, and 
immunofluorescence.
Expression and distribution of collagen
Excessive collagen deposition in the extracellular matrix 
is a hallmark of liver fibrosis. Collagen distribution was 
determined by trichrome staining using a kit from ScyTek 
Laboratories (TGG500, West Logan, UT, USA) according to 
the directions of the manufacturer. The stage of liver fibrosis 
was determined in a blinded fashion by using trichrome-
stained slides according to the METAVIR scoring system.22 
We used the METAVIR system because, through extensive 
intraobserver variation studies, this system was designed 
to be simple, consistent, and reproducible.23 Similarly, 
this system has been applied to a variety of chronic liver 
diseases,24 including biliary disorders such as primary biliary 
cirrhosis25 and primary sclerosing cholangitis.26 Moreover, it 
is noteworthy that the staging components of the most com-
monly employed scoring systems, especially when applied 
to advanced liver disease, yield similar results.
TGFβ1 immunohistochemistry
After rehydration, 4-µm paraffin-embedded sections on 
glass slides were incubated in 3% hydrogen peroxide to 
block the endogenous peroxidase activity. Sections were Clinical and Experimental Gastroenterology 2010:3
Figure  1  Trichrome  staining  for  collagen  in  human  biliary  atresia.  Trichrome 
staining was done as described in the Materials and methods section. A) Thick bands 
of collagen septa (green) separating nodular liver tissue. B) Trichrome staining of a 
healthy control liver (original magnification ×10).
Abbreviation: BA, biliary atresia.
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then blocked by incubation in 3% bovine serum albumin 
in phosphate-buffered saline (PBS). A monoclonal mouse 
antihuman TGFβ1 antibody (Abcam 27969, Cambridge, 
MA, USA) that reacts to both monomeric and dimeric forms 
of TGFβ1 was applied at a dilution of 1:500 (diluted in 3% 
bovine serum albumin) and incubated at 4°C overnight. 
After a 5-min wash in PBS, the slides were treated with goat 
antimouse IgG horseradish peroxidase-labeled secondary 
antibodies (Bio-Rad, Cat#17065, Hercules, CA, USA) at 
a dilution of 1:500 (diluted in 3% bovine serum albumin) 
for 30 min at room temperature. Bound antibodies were 
detected with an ABC kit (Vector Laboratories, Burlingame, 
CA, USA). The slides were stained with diaminobenzidine, 
washed, counterstained with Mayer’s hematoxylin, dehy-
drated, treated with xylene, and mounted. As a control to 
immunostaining, separate sections from both BA and normal 
human liver tissues were incubated with and without primary 
and appropriate isotyped antibodies.
intensity of TGFβ1 immunostaining
The intensity of the TGFβ1 immunostaining was determined 
by using ImageJ software (http://rsb.info.nih.gov/ij). From 
each slide, five random portal and lobular areas were analyzed 
with a color histogram using a color deconvolution plug-in 
routinely used for diaminobenzidine staining.27
Immunofluorescence
After rehydration, 4-µm sections of paraffin-embedded 
tissue on glass slides were blocked by incubation in 4% 
bovine serum albumin in PBS. A monoclonal TGFβ1 mouse 
antihuman antibody (Abcam 27969) and a polyclonal rabbit 
anti-α-SMA (Abcam 5694) were applied to the slides at the 
dilution of 1:100 (diluted in 4% bovine serum albumin) and 
incubated at 4°C overnight. After being washed for 5 min in 
PBS, the slides were treated with fluorescently labeled sec-
ondary antibodies at a dilution of 1:500 (diluted in 4% bovine 
serum albumin) for 45 min at room temperature. Secondary 
antibodies used included donkey antimouse IgG (Alexa 
Fluor® 488, Invitrogen A21202, Carlsbad, CA, USA) and 
donkey antirabbit IgG (Alexa Fluor 594, Invitrogen A21207). 
Afterward, the tissue sections were washed with PBS and 
mounted with UltraCruz® medium (sc-24941) containing 
4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining. 
As a control for the technique and nonspecific Fc receptor 
binding, BA and normal human liver tissue sections were 
incubated with and without primary or secondary antibody 
as well as isotyped rabbit (ab27478) and mouse (ab18447) 
antibodies.
Data analysis
Student t-test was applied by using GraphPad software (La 
Jolla, CA, USA) to compare the means of color pixel histo-
grams (representing the intensity of TGFβ1 expression) and 
METAVIR scores. Values are presented as mean ± standard 
error of the mean. A P value of ,0.05 was considered 
  statistically significant.
Results
Expression and distribution  
of collagen in advanced BA
The purpose of trichrome staining was two-fold: 1) to deter-
mine the distribution of collagen to serve as a reference for 
the distribution of TGFβ1 and 2) to determine the extent of 
fibrosis by the METAVIR scoring system. In this system, F0 
represents no fibrosis; F1, portal fibrosis without septa; F2, 
portal fibrosis and few septa; F3, numerous septa extending 
to adjacent portal tracts or terminal hepatic venules; and 
F4, cirrhosis. The mean METAVIR score was 3.8 ± 0.8 
(N = 30, minimum 3, maximum 4), consistent with advanced 
cirrhosis, a typical feature of end-stage liver disease due 
to BA. A representative trichrome-stained slide is shown 
in Figure 1A showing thick collagenous bands interspersed 
between nodular liver tissues, thus producing portal-to-portal 
bridging fibrosis, a histological pattern typical for biliary 
cirrhosis. In contrast, healthy control livers (Figure 1B) had 
only minimal collagen staining in portal areas, consistent 
with noted F0 METAVIR scores.
hepatic distribution of TGFβ1  
and α1-sMA in advanced BA
In explant liver specimens, as shown in Figure 2A, hetero-
geneous overexpression of TGFβ1 is evident in the hepatic Clinical and Experimental Gastroenterology 2010:3
Figure 2 immunohistochemical localization of TGFβ1 protein in human BA. Specific 
staining of TGFβ1 protein is represented by brown coloration. A) The expression of 
TGFβ1 in BA, which is mostly in lobular areas. B) TGFβ1 expression in a liver used 
as control. C) Expression of α1-sMA in BA. D) α1-sMA from a liver used as control 
(original magnification ×10).
Abbreviations:  TGFβ1,  transforming  growth  factor  beta-1;  BA,  biliary  atresia; 
sMA, smooth muscle actin.
P ≤ 0.05
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Figure 3 Pattern of hepatic distribution of TGFβ1 protein in human BA. Liver 
sections  were  obtained  from  archived  explant  specimens  from  patients  who 
required LT due to BA (n = 9). The control sections were procured from the 
biopsies of living related liver donors. The expression of TGFβ1 was performed by 
immunostaining, which was quantified by using ImageJ software. From each slide, 
five random portal and lobular areas were analyzed. GraphPad software was used to 
analyze the data using t-test to compare the means of color pixel histograms from 
portal and lobular areas. A P value # 0.05 was considered significant.
Abbreviations: BA, biliary atresia; NS, not significant; TGFβ1, transforming growth 
factor beta-1; LT, liver transplantation.
Figure 4 Characterization of hepatic cellular sources of TGFβ1 in human BA. 
A) Immunofluorescence staining for TGFβ1 (green, original magnification ×20). 
B)  Immunofluorescence  staining  for  α-SMA  (red,  original  magnification  ×20). 
C) Merge image of A and B. D) The original magnification ×60 of the box in C. 
heterogeneous expression of TGFβ1 is seen in hepatocytes.
Abbreviations:  TGFβ1,  transforming  growth  factor  beta-1;  BA,  biliary  atresia; 
sMA, smooth muscle actin.
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parenchyma, more in the center of the liver nodules, 
although hepatocytes close to collagen in fibrous septa 
are also noted to express a low level of TGFβ1 protein. 
Conversely, in livers used as control, the distribution of 
TGFβ1 is virtually all interstitial and quite homogeneous 
throughout the hepatic parenchyma (Figure 2B). Contrary 
to TGFβ1 expression, α-SMA is expressed mostly in the 
portal structures and the adjacent fibrous septa enacting 
lobulation of the parenchyma (Figure 2C). As expected, 
in liver specimens used as control, α-SMA expression is 
restricted to portal structures (  Figure 2D). Consistent with 
the TGFβ1 expression in hepatic parenchyma, quantitative 
analysis of TGFβ1 protein content was significantly higher 
in lobular versus portal areas (89 ± 6 versus 10 ± 1 arbitrary 
units, P # 0.05) in BA (Figure 3). In contrast, in livers used 
as control, lobular versus portal TGFβ1 expression was 
not significantly different, although a trend of more portal 
expression was noted (10 ± 1.6   versus 19 ± 5 arbitrary 
units, P = 0.11; Figure 3). These results were in agreement 
with the coimmunofluorescence staining, which showed no 
significant localization of α-SMA and TGFβ1 (Figure 4C 
and D). Once again, most of the TGFβ1 expression is 
seen in parenchymal cells (Figure 4A, C and D), whereas 
α-SMA expression is mostly restricted to the area of fibrous 
septa (Figure 4B). The summary of these findings is that 
in advanced BA, TGFβ1 is mainly expressed by hepatic 
parenchymal cells.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Discussion
The present report documents the novel observation that 
hepatic TGFβ1 is principally immune-localized to parenchy-
mal cells in advanced liver disease due to BA. Additional novel 
observations are as follows: 1) TGFβ1 expression is homog-
enous, interstitial, and quantitatively more portal than lobular 
in normal human liver; 2) in contrast to normal human liver, 
heterogeneous lobular expression of TGFβ1 becomes more 
significant in advanced BA; and 3) more TGFβ1 is expressed 
in the center of nodules, away from fibrous septa, suggesting 
the existence of paracrine interactions between parenchymal 
cells and fibrogenic MFB in advanced cirrhosis due to BA.
This report unveils the significance of parenchymal cells 
in the injury-repair interactions at advanced stages of BA. In 
progressive cholestatic disorders such as BA, extracellular 
matrix deposition typically starts in periportal areas, extends 
to produce bridging, and ultimately leads to frank cirrhosis. 
Primary events executing fibrogenesis entail recruitment 
and proliferation of specialized collagen-producing MFBs. 
Because of their well-known phenotypic evolution to become 
MFBs, HSCs are known as prototypic profibrogenic cells 
in the hepatic parenchyma. Depending on the type of liver 
injury, other cell types such as resident portal fibroblasts,28 
biliary duct cells,29 and even hepatocytes30 can also   contribute 
to the pool of extracellular matrix-producing MFBs. TGFβ1 
plays an overarching role orchestrating key fibrogenic 
events such as MFB recruitment and proliferation as well 
as upregulation of extracellular matrix protein synthesis. 
Fundamental questions emerging from the main finding of 
this work remain: what are the triggers for TGFβ1 expres-
sion in hepatocyte; what are the roles of HSC and Kupffer in 
TGFβ1 expression from hepatocyte; and what are molecular 
mechanisms of fibrogenic interactions between hepatocytes 
and other parenchymal and nonparenchymal cells? Given 
that cholestasis and oxidative stress are the most important 
pathophysiologic mechanisms of liver injury in BA,23 elu-
cidation of the fibrogenic role of bile acids and oxidative 
stress will be the next most logical step in the investigation 
of hepatic overexpression of TGFβ1. Hepatic retention 
of hydrophobic bile acids due to biliary obstruction plays 
an important role in the pathogenesis of cholestatic liver 
injury.31–33 This is exemplified by bile acid-induced liver 
injury in children with progressive familial intrahepatic 
cholestasis type 2. In this disorder, homozygous mutations in 
the gene encoding the canalicular membrane bile salt export 
pump impair hepatocellular secretion of conjugated bile 
acids, resulting in elevated hepatic bile acid concentrations 
and progressive cholestasis, fibrosis, and liver failure.34 Simi-
larly, hydrophobic bile acids are known to cause oxidative 
stress35 and apoptosis,36 causing perpetual hepatocyte loss 
and fibrosis.37
TGFβ1 is best known as a fibrogenic cytokine, a role well 
documented in both human diseases and transgenic mouse 
models of hepatic TGFβ1 overexpression.38,39 However, 
further work is required to determine the precise biological 
or pathological significance of the observations presented in 
this report. Several biological traits peculiar to TGFβ1 need 
careful consideration for the appropriate interpretation of 
these results. First, apart from its well-known profibrogenic 
actions, TGFβ1 also controls diverse cellular functions such 
as proliferation, differentiation, adhesion, migration, matrix 
expression, matrix degradation, and immune surveillance. 
Determined by the context, a stringent balance of these 
actions is required for normal tissue homeostasis. Second, 
although TGFβ1 transcription occurs in many cell types, its 
translation and secretion appear to be under strict regulation, 
a phenomenon explaining the well-documented discrepancy 
between TGFβ1 protein levels and corresponding mRNA 
expression.40,41 Therefore, in addition to knowledge of 
pathophysiological context, temporally stacked examinations 
are necessary to determine which pathological events under-
pin parenchymal TGFβ1 expression in BA. A major impedi-
ment in this regard is the ethical restriction on interval liver 
biopsies after Kasai operation. Therefore, the interpretation 
of single point examinations (mRNA or protein-based) such 
as those adopted in this and earlier reports42,43 is somewhat 
limited. Nonetheless, this work provides a framework for the 
synthesis of testable hypotheses.
For example, although parenchymal cells can produce 
extracellular matrix proteins,44 the lack of pericellular 
extracellular matrix in these livers and the presence of char-
acteristic portoportal bridging (Figure 1) strongly support 
paracrine fibrogenic interactions between hepatocytes and 
MFBs in advanced BA. Similarly, because cholestasis and 
oxidative stress are common pathophysiologic mechanisms 
of liver injury in advanced BA, it is reasonable to postulate 
that coupled actions of toxic bile acids and mediators of 
oxidative stress could be the underlying triggers for hepatic 
upregulation of TGFβ1. Our unpublished data from tissue 
culture studies support this hypothesis. Similarly, Kupffer 
cell activation, a frequent source of oxidative stress, is 
known to amplify the TGFβ1 signal pathway,45 supporting 
the hypothesis that Kupffer cells may have a role in hepa-
tocyte overexpression of TGFβ1. These hypotheses are the 
focus of our ongoing investigations. Similarly, questions 
pending resolution through further research concern the Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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impact of oxidative stress and toxic bile acids on expression 
of noncollagenous matrix proteins and matrix metalloprotei-
nases; whether noncanonical TGFβ1 signaling pathways inter-
sect with canonical pathway; and, if so, what the pathological 
and molecular determinants of these intersections are.
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